Regulatory T-Cell (Tregs) Therapies Market Size, Share and Trends Analysis, By Source (Autologous Tregs and Allogeneic Tregs), By Therapeutic Type (Polyclonal Tregs, Antigen-Specific Tregs, CAR-Tregs, and Engineered Tregs), By Indication, By End-Use, and By Region, Forecast 2025-2032

egulatory T-Cell (Tregs) Therapies Market Overview and Key Insights:

The Regulatory T-Cell (Tregs) therapies market size reached USD 16.7 million in 2024 and is expected to register a revenue CAGR of 44.6% during the forecast period. Regulatory T cells (Tregs) are CD4+ T cells that exhibit anti-inflammatory capabilities. In animal models, they can reduce allograft rejection and alleviate autoimmune disease symptoms. Regulatory T cells (Tregs) have been shown to play an important role in preventing pathological immune responses, and there is emerging evidence that they also contribute directly to tissue homeostasis by promoting tissue regeneration and repair.

Market Drivers:

Rising prevalence of autoimmune disorders and transplant rejections is a key driver of revenue growth in the Regulatory T-Cell (Tregs) therapies market. According to the Lupus Foundation of America, lupus affects around 1.5 million Americans and at least five million individuals worldwide. Ninety percent (90%) of patients with lupus are female. Most lupus patients get the condition between the ages of 15 and 44. Systemic lupus accounts for over 70% of all instances of lupus. In approximately half of these cases, a major organ or tissue in the body, such as the heart, lungs, kidneys, or brain will be affected. Lupus affects two to three times as many African American, Hispanic/Latina, Asian American, Native American, Alaska Native, Native Hawaiian, and other Pacific Islander women than it does white women.

Advancements in cell therapy and immunomodulation are also driving market revenue growth. Researchers rely on therapeutic techniques based on modified T cells, which require the efficient, safe, and stable production of specific genetic alterations. Viral gene transduction technology primarily enables this process. Gamma-retroviruses and lentiviruses stably integrate into the host genome, ensuring consistent gene expression in transduced human and mouse T cells. Because of its high transduction effectiveness, viral gene transfer is the most utilized method for producing CAR-T cells, including CAR-Treg cells. In contrast, adenoviruses and adeno-associated viruses can only cause transitory gene expression, which is a drawback when employing proliferating cells.

On March 2023, Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. have announced a collaboration to use their scientific and clinical expertise, as well as their respective technology platforms, to discover, develop, and commercialize novel regulatory T cell (Treg) therapies for autoimmune diseases. The collaboration will combine Regeneron’s industry-leading VelociSuite technologies for discovering and characterizing fully human antibodies and T cell receptors (TCRs) with Sonoma Biotherapeutics’ innovative approach to developing and manufacturing gene-modified Treg cell therapies.

Market Opportunity:

Development of allogeneic and off-the-shelf therapies act as an opportunity for Regulatory T-Cell (Tregs) therapies market. Genetic engineering of allogeneic Treg as an off-the-shelf product would enable cells from a single donor to treat multiple patients, lowering the cost per dose and increasing treatment flexibility. To improve allo-Treg persistence, delete β-2 microglobulin and CIITA to remove MHC-I and -II antigens, respectively.

Allogeneic HCT continues to offer a curative option for many hematologic malignancies, although GVHD typically worsens outcomes and remains a major cause of morbidity and death. Current GVHD preventive treatments primarily use extensive immunosuppression, which can delay immune reconstitution and increase complications. Preclinical and early clinical investigations have shown that donor-derived Tregs, which naturally suppress immune responses, can effectively reduce GVHD while preserving graft-versus-tumor effects.

Recent Trends:

Emerging trends include antigen-specific Treg engineering, CAR-Tregs, gene editing technologies, and integration with nanotechnology and drug delivery systems.

Tregs are important regulators of tissue repair, autoimmune disorders, and cancer. Adoptive Tregs can treat and reverse immune-mediated diseases like GVHD, autoimmunity, and organ transplant rejection. CRISPR gene editing improves Treg selectivity, survival, and function in inflammatory disorders. CRISPR-Cas9 can help restore Treg accumulation in inflammatory disorders. In metabolic illnesses like obesity, Tregs can maintain visceral adipose tissue (VAT) balance and metabolic health. In the engineering of vascular graft transplantation, reprogrammed Tregs with a CRISPR-Cas9 nanocarrier targeted the Treg surface marker CD25, increased anti-inflammatory cytokines, and improved nerve regeneration.

On July 2025, Integrated DNA Technologies (IDT), a global genomics pioneer, is redefining translational gene editing with new improvements to its end-to-end CRISPR platform. These enhanced CRISPR translational research solutions are intended to help researchers speed additional CRISPR-based therapeutics.

Restraints & Challenges:

Treg medicines have enormous potential for combating autoimmune illnesses, preventing transplant rejection, and treating inflammatory conditions by utilizing the body’s innate immune regulators. However, Treg therapies are more difficult than other adoptive cell therapies, such as CAR-T. While all cell therapy manufacturing is difficult, the scarcity of Tregs, combined with the vital requirement for a highly pure cell population, makes their development and production even more difficult.

The production of Treg therapeutics involves problems because to the requirement for a highly pure population of uncommon and difficult-to-isolate cells. Achieving a pure Treg population necessitates several steps, including de-bulking to remove undesirable cells and purification with magnetic beads and flow sorting. These stages require a significant number of resources, both financially and in terms of time spent outside of optimal culture conditions, which can have an influence on cell health.

Source Segment Insights and Analysis:

Based on the Source, the Regulatory T-Cell (Tregs) Therapies market is segmented into Autologous Tregs and Allogeneic Tregs.

Autologous Tregs segment contributed the highest market share in 2024. Adoptive T cell therapy (ACT) for autoimmunity often uses polyclonal autologous lymphocytes retrieved and separated from the treated subject’s peripheral blood. Although healthy individuals’ peripheral blood typically contains enough Tregs, they have a terminally differentiated memory phenotype, reducing not only expansion capacity but also the likelihood of successful engraftment and survival. Most Treg manufacturing methods were established and verified using autologous polyclonal Treg products.

On September 2024, PolTREG S.A., a clinical-stage biotechnology company exploring cellular therapeutics for a variety of autoimmune illnesses, has announced the start of a study using CAR-Treg cells in a humanized mouse model of neuroinflammatory disease. PolTREG’s CAR-Treg cells are developed from its PTG-007 Treg cells, which are a promising autologous polyclonal product candidate for type 1 diabetes.

Therapeutic Type Segment Insights and Analysis:

Based on the therapeutic type, the Regulatory T-Cell (Tregs) Therapies market is segmented into polyclonal Tregs, antigen-specific Tregs, CAR-Tregs (Chimeric Antigen Receptor Tregs), and engineered Tregs.

Polyclonal Tregs segment contributed the largest market share in 2024. Polyclonal Treg-based cell therapy techniques have produced early promising results in the prevention of graft-versus-host disease following allogeneic hematopoietic stem cell transplantation and the maintenance of C-peptide levels in type 1 diabetes. Several clinical trials involving polyclonal Treg therapy for the treatment of autoimmune disease have been completed or are ongoing. Further clinical trials using polyclonal Tregs as a cell-based therapeutic are presently underway in T1D and other autoimmune illnesses to determine the optimal treatment regimen in terms of cell counts transferred, number of doses necessary, and duration between treatments.

On June 2025, PolTREG S.A., a clinical-stage biotechnology firm exploring cellular therapeutics for a variety of autoimmune illnesses, has announced the formation of Immuthera, a wholly owned subsidiary based in Delaware. PolTREG has established a platform for the creation of a variety of cellular therapeutics, including polyclonal Tregs, CAR-TREGs, multi-edited/allogeneic CAR-Tregs, antigen-specific Tregs, and RNA immunotherapies.

Indication Segment Insights and Analysis:

Based on the Indication, the Regulatory T-Cell (Tregs) therapies market is segmented into autoimmune diseases, transplantation, Graft-Versus-Host Disease (GvHD), inflammatory and allergic disorders, oncology, and others.

Autoimmune diseases segment contributed the largest market share in 2024. It is further segmented into Type 1 diabetes, multiple sclerosis, rheumatoid arthritis, Inflammatory Bowel Disease (IBD), and Systemic Lupus Erythematosus (SLE). According to the Australian Institute of Health and Welfare, in 2022, it is estimated that around 514,000 Australians will have rheumatoid arthritis. On 2023, rheumatoid arthritis represented for 2.0% of overall illness burden and 16% of the total disease burden across all musculoskeletal disorders. In 2020–21, healthcare providers spent an estimated AUD 966.1 million on treating and managing rheumatoid arthritis, representing 0.6% of total healthcare spending and 6.6% of total spending on musculoskeletal diseases. In 2022, rheumatoid arthritis caused 1,322 deaths, or 5.1 deaths per 100,000 people, accounting for 0.7% of all deaths.

On June 2023, AstraZeneca has formed an exciting collaboration, exclusive option, and license agreement with Quell Therapeutics to develop multiple engineered T-regulator (Treg) cell therapies with the potential to be curative in Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD) indications. According to the terms of the agreement, Quell will use its unique toolbox of Treg cell engineering modules, including its novel Foxp3 Phenotype Lock, to generate autologous multi-modular Treg cell treatment candidates for major autoimmune disease indications.

Geographical Outlook:

Regulatory T-Cell (Tregs) therapies market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Regulatory T-Cell (Tregs) Therapies Market:

North America is registered to have highest market share in Regulatory T-Cell (Tregs) therapies market in 2024. This is mainly driven by rising prevalence of autoimmune disorders and transplant rejections and advancements in cell therapy and immunomodulation. According to the Autoimmune Association, autoimmune diseases affect over 50 million Americans (8% of the U.S. population), and current data suggests that the prevalence is increasing.  Epidemiological studies show that the incidence of global autoimmune diseases has increased by 19.1% per year, with rheumatological diseases such as Sjögren’s and lupus increasing by 7.1% each year.

Although some experts believe that the number of new occurrences of autoimmune illnesses is alarming and approaching epidemic proportions, autoimmune research is moving forward with increasing funding and the development of better diagnostic tools and therapies. The National Institutes of Health (NIH) has significantly boosted its investment in autoimmune disease research in recent years, with funding rising from USD 800 million to more than USD 1 billion by 2022.

On May 2025, AGC Biologics has established a collaboration with Quell Therapeutics, a clinical-stage biotechnology startup that pioneered modified T-regulatory (Treg) cell therapeutics. This collaboration promotes the development of several Treg cell therapy medication candidates for severe immunological diseases. 

Asia Pacific Regulatory T-Cell (Tregs) Therapies Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period. According to the International Diabetes Federation (IDF), the number of diabetics in the SEA Region is expected to increase by 73%, reaching 185 million by 2050. Diabetes will climb by 36% throughout the same time span, reaching 13.2%. At 42.7%, the region has the third highest rate of undiagnosed diabetes. Hyperglycemia affects the most pregnancies, accounting for 27.8% of the total. Only 12 billion USD were spent on diabetes in the region, accounting for only 1% of total spending worldwide, even though the region is home to 18.2% of the world’s diabetics.

On March 2025, RegCell, Inc. has announced the completion of an oversubscribed seed round of USD 8.5 million seed funding and its transfer to a US-based firm. RegCell received up to USD 37.3 million in non-dilutive funding (¥5.6 billion) from Japan’s Agency for Medical Research and Development (AMED). This financing will help to improve RegCell’s epigenetic reprogramming platform through clinical proof-of-concept, thereby validating RegCell’s technology and Japan’s commitment to innovation.

Europe Regulatory T-Cell (Tregs) Therapies Market:

Europe is expected to have considerable market share in 2024. According to the National Rheumatoid Arthritis Society, Rheumatoid Arthritis (RA) affects approximately 1% of the UK population, which equates to more than 450,000 people. It affects more women than men, approximately two to three times as many women. The most frequent ages for persons to acquire RA are 40 to 60, or somewhat older for men.

Furthermore, awareness towards RA is also driving the market growth. For instance, on January 2025, Johnson & Johnson has awarded GBP 3.5 million to researchers at the University of Birmingham to investigate the mechanisms of response and non-response to biologic and targeted synthetic therapies in rheumatoid arthritis. In this new study, researchers will collect biopsies from patients before and throughout normal care to better understand why some patients respond better than others, and, more crucially, what happens when a patient does not respond to therapy.

On September 2024, Quell Therapeutics Ltd, a global leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions caused by the immune system, and eXmoor Pharma, a full-service cell and gene therapy (CGT) manufacturing partner, have announced a strategic partnership to manufacture multiple autologous engineered CAR-Treg cell therapies in Quell’s pipeline that target autoimmune diseases. Quell uses its groundbreaking Foxp3 Phenotype Lock technology and unique multi-modular platform to create and manufacture highly tailored Treg cell therapies that are efficiently targeted, have robust immune regulation function, and remain durable and stable in the target tissue.

Competition Analysis:

The Regulatory T-Cell (Tregs) Therapies market is characterized by a fragmented structure, with several players competing across various segments and regions. list of major players included in the Regulatory T-Cell (Tregs) Therapies market report are:

• Abata Therapeutics
• PolTREG S.A.
• Kyverna Therapeutics
• Sonoma Biotherapeutics
• Quell Therapeutics
• Sangamo Therapeutics
• GentiBio
• Parvus Therapeutics Inc.
• Mozart Therapeutics
• Egle Therapeutics
• Nektar Therapeutics
• Coya Therapeutics, Inc
• TR1X, Inc.
• Egle Therapeutics
• Cugene, Inc. 

Strategic Developments in Regulatory T-Cell (Tregs) Therapies Market:

• In August 2024, Abata Therapeutics, a business dedicated to altering lives through Treg therapeutics for severe autoimmune and inflammatory illnesses, announced that it has secured an equity investment from Bristol Myers Squibb to assist the development of Treg cell therapy products. Their investment helps Abata continue its clinical development, with ABA-101 trials in progressive multiple sclerosis set to begin soon.
• In August 2023, Kyverna Therapeutics, a clinical-stage cell therapy business with the goal of developing a new class of medicines for autoimmune illnesses, has announced the completion of an oversubscribed USD 60 million Series B fundraising round extension, bringing the total Series B financing round to USD 145 million. This Series B extension will fund Kyverna’s clinical trials in the United States and Europe, allowing us to move faster toward delivering potentially revolutionary and life-saving treatments to patients

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of The Regulatory T-Cell (Tregs) Therapies Market Report:

The Regulatory T-Cell (Tregs) Therapies market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Source Outlook (Revenue, USD Million; 2022-2032)
  • Autologous Tregs
  • Allogeneic Tregs

• Therapeutic Type Outlook (Revenue, USD Million; 2022-2032)
  • Polyclonal Tregs
  • Antigen-Specific Tregs
  • CAR-Tregs (Chimeric Antigen Receptor Tregs)
  • Engineered Tregs

• Indication Outlook (Revenue, USD Million; 2022-2032)
  • Autoimmune Diseases
    • Type 1 Diabetes
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Inflammatory Bowel Disease (IBD)
    • Systemic Lupus Erythematosus (SLE)
  • Transplantation
  • Graft-Versus-Host Disease (GvHD)
  • Inflammatory and Allergic Disorders
  • Oncology
  • Others

• End-Use Outlook (Revenue, USD Million; 2022-2032)
  • Hospitals and Clinics
  • Pharmaceutical and Biotechnology Companies
  • Research Institutes and Academic Centers
  • Contract Research Organizations (CROs)

• Regional Outlook (Revenue, USD Million; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about the Regulatory T-Cell (Tregs) Therapies market report